PharmacoEconomics & Outcomes News 625 - 2 Apr 2011 Vaccine sustainability in resource- poor countries In resource-poor countries, increases in the use of hepatitis B and Haemophilus influenzae vaccines, supported by GAVI, * will need to be sustained through strengthening supply chains, increasing national responsibility, and adjusting funding schemes, according to researchers from Switzerland and Denmark. The researchers evaluated data from 65 countries that introduced the hepatitis B vaccine and 38 countries that introduced the Haemophilus influenzae vaccine, with assistance from GAVI, between the years 2000 and 2008. Their study was focused on the trends in prices and volumes of vaccines offered, sources of finance and program budgets for national immunisation programmes, and the availability of national advisory bodies. The results of the study indicate that the types of vaccine supplied varied substantially in response to changes in the number of suppliers and also with the increased availability of combination vaccine products. The introduction of vaccines was also associated with an increase in the financial budget of national programmes, with new vaccines accounting for more that half of the increase; GAVI contributions to budgets increased from 25% to 46%. The researchers also state that national advisory bodies decided on fewer than 20% of vaccine introductions. * Global Alliance for Vaccines and Immunisation Zuber PL, et al. Sustaining GAVI-supported vaccine introductions in resource-poor countries. Vaccine : 24 Feb 2011. Available from: URL: http://dx.doi.org/10.1016/ j.vaccine.2011.02.042 803052303 1 PharmacoEconomics & Outcomes News 2 Apr 2011 No. 625 1173-5503/10/0625-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Vaccine sustainability in resource-poor countries

Download PDF Report

Upload
vutruc
View
213
Download
1

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 625 - 2 Apr 2011

Vaccine sustainability in resource-poor countries

In resource-poor countries, increases in the use ofhepatitis B and Haemophilus influenzae vaccines,supported by GAVI,* will need to be sustained throughstrengthening supply chains, increasing nationalresponsibility, and adjusting funding schemes,according to researchers from Switzerland andDenmark.

The researchers evaluated data from 65 countries thatintroduced the hepatitis B vaccine and 38 countries thatintroduced the Haemophilus influenzae vaccine, withassistance from GAVI, between the years 2000 and2008. Their study was focused on the trends in pricesand volumes of vaccines offered, sources of finance andprogram budgets for national immunisationprogrammes, and the availability of national advisorybodies.

The results of the study indicate that the types ofvaccine supplied varied substantially in response tochanges in the number of suppliers and also with theincreased availability of combination vaccine products.The introduction of vaccines was also associated with anincrease in the financial budget of national programmes,with new vaccines accounting for more that half of theincrease; GAVI contributions to budgets increased from25% to 46%. The researchers also state that nationaladvisory bodies decided on fewer than 20% of vaccineintroductions.* Global Alliance for Vaccines and Immunisation

Zuber PL, et al. Sustaining GAVI-supported vaccine introductions in resource-poorcountries. Vaccine : 24 Feb 2011. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2011.02.042 803052303